Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Minnesota: - Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Miller-Dwan Hospital — Duluth, Minnesota
- Essentia Health Hibbing Clinic — Hibbing, Minnesota
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Minnesota: - Research Site — Burnsville, Minnesota
- Research Site — Duluth, Minnesota
- Research Site — Minneapolis, Minnesota
- Research Site — Rochester, Minnesota
Phase 3 Recruiting Industry
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…
Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Minnesota: - Minnesota Oncology Hematology, PA ( Site 8003) — Edina, Minnesota
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…
Sponsor: Mayo Clinic
NCT ID: NCT06915727
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Minnesota Oncology Hematology PA-Chaska — Chaska, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Minnesota: - USOR Minnesota Oncology Hematology — Maplewood, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Minnesota: - Research Site 121 — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Minnesota: - Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Minnesota: - Health Partners Frauenshuh Cancer Center — Saint Louis Park, Minnesota
- Health Partners Cancer Center at Regions Hospital — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1 Recruiting Industry
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in Minnesota: - Normunity Investigational Site — Minneapolis, Minnesota
Phase 1 Recruiting Industry
This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab…
Sponsor: Fate Therapeutics
NCT ID: NCT07216105
Sites in Minnesota: - University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Minnesota: - Mayo Clinic (Rochester) — Rochester, Minnesota
Recruiting Industry
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Sponsor: Tempus AI
NCT ID: NCT06163534
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Recruiting Academic/Other
The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biologica…
Sponsor: Case Western Reserve University
NCT ID: NCT00288119
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
NA Recruiting Industry
The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after a…
Sponsor: Qurasense
NCT ID: NCT07281599
Sites in Minnesota: - Planned Parenthood North Central States — Minneapolis, Minnesota
NA Recruiting Academic/Other
This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy use…
Sponsor: Mayo Clinic
NCT ID: NCT04567771
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Recruiting Academic/Other
Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatm…
Sponsor: Children's Hospitals and Clinics of Minnesota
NCT ID: NCT03382158
Sites in Minnesota: - Children's Minnesota — Minneapolis, Minnesota
Recruiting Academic/Other
This study is being done to see whether signals from a device that monitors blood flow through the free flap can be recorded and converted from an audible signal, like a heartbeat, into a visual signal. Researchers plan to use this informa…
Sponsor: Mayo Clinic
NCT ID: NCT07823283
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
NA Recruiting Industry
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Eligible parti…
Sponsor: New Phase Ltd.
NCT ID: NCT07224464
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota